Evidence map›Paper›PMID 39720060›Full record

ArticleHeliyon2024

Synthetic approaches for novel fused pyrimidine derivatives: Design, structural characterization, antiviral, antitumor, and molecular docking evaluation.

Fatmah O Sefrji, Abdulmajeed F Alrefaei, Mohammed A Imam, Gadeer R S Ashour, Matokah M Abualnaja, Roba M S Attar, A A A Darwish, Nashwa M El-Metwaly

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fatmah O SefrjiDepartment of Biology, College of Science, Taibah University, Al-Madinah Al-Munawarah, Saudi Arabia.
Abdulmajeed F AlrefaeiDepartment of Biology/Genetic and Molecular Biology Central Laboratory (GMCL), Jamoum University College, Umm Al-Qura University, Makkah, 2203, Saudi Arabia.
Mohammed A ImamDepartment of Medical Microbiology and Parasitology, Qunfudah Faculty of Medicine, Umm Al-Qura University, Al-Qunfudah, 21961, Saudi Arabia.
Gadeer R S AshourDepartment of Chemistry, College of Science, Umm Al-Qura University, Makkah, 24230, Saudi Arabia.
Matokah M AbualnajaDepartment of Chemistry, College of Science, Umm Al-Qura University, Makkah, 24230, Saudi Arabia.
Roba M S AttarDepartment of biological sciences/ Microbiology, Faculty of Science, University of Jeddah, Jeddah, 21959, Saudi Arabia.
A A A DarwishAdvanced Materials Research Laboratory, Department of Physics, Faculty of Science, University of Tabuk, Tabuk, 71491, Saudi Arabia.
Nashwa M El-MetwalyDepartment of Biology, College of Science, Taibah University, Al-Madinah Al-Munawarah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The goal of this work was to synthesize new compounds for anticancer evaluation as a trial to obtain new antitumor agents with higher activity and fewer side effects. Therefore, the precursor 2,2'-(1,4-phenylenebis (thiazole-4,2-diyl))bis (3-(dimethylamino)acrylonitrile)

Indexed as

AntiviralCytotoxicityMolecular dockingPyrimidineThiazole

Identifiers

PMID39720060
PMCPMC11667641

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.